Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IGMS,322456000.0,25594700,30089000,,-38714000,,-38714000,8649000,0,-38738000,-38738000,,,,,,0,0,38738000,0,24000,,-38714000,-38714000,581056000.0,28208000.0,322456000.0,661000.0,350664000.0,320000.0,-258918000.0,-2000.0,831000.0,246049000.0,19062000.0,-2000.0,39283000.0,290161000.0,20389000.0,35396000.0,4853000.0,23220000.0,-360000.0,20058000.0,-33000.0,4728000.0,564000.0,-6327000.0,-597000.0,-26352000.0,1413000.0,6581000.0,-3162000.0,,271099000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,29.79,0.70928574,42.0 - 133.0,-61.21,-0.46022555,42.0,133.0,1617134400,1635942600,1636374600,-26.204,-1.96,-5.03,0.81449497,70.5 - 72.09,71.21,0.0,0.0,8,10,finmb_315179920,NasdaqGS,"IGM Biosciences, Inc.",USD,146278,105200,-14.272366,8.354,77.34857,-5.558571,-0.07186391,78.346085,-6.5560837,-0.08368106,2299146496,-36.627552,8.593488,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"IGM Biosciences, Inc.",71.79,1630526402,0.58000183,71.66,72.09,70.5,91255,,,,133.0,42.0,77.35,78.35,146.28k,105.2k,25.59M,,7.98M,43.15%,65.31%,2.95M,23.02,36.77%,9.20%,2.95M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-24.96%,-43.54%,,,,-39.16M,-113.1M,-115.25M,-26.20,,281.44M,8.78,12.64M,3.92,15.22,8.35,-92.45M,-74.58M,Value,94043,Healthcare,144,9,8,"IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.",Mountain View,650 965 7873,CA,10,1609372800,1625097600,5,United States,http://igmbio.com,86400,8,325 East Middlefield Road,Biotechnology
t-1,IGMS,355610000.0,25594700,23572000,,-31644000,,-31644000,8134000,0,-31706000,-31706000,,,,,,0,0,31706000,0,62000,,-31644000,-31644000,575481000.0,24864000.0,355610000.0,,380474000.0,319000.0,-220204000.0,14000.0,886000.0,252376000.0,14818000.0,14000.0,38411000.0,341177000.0,,79298000.0,5661000.0,45684000.0,1045000.0,39611000.0,-53000.0,-4707000.0,365000.0,11296000.0,-418000.0,-28262000.0,673000.0,6371000.0,-6073000.0,,326359000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,29.79,0.70928574,42.0 - 133.0,-61.21,-0.46022555,42.0,133.0,1617134400,1635942600,1636374600,-26.204,-1.96,-5.03,0.81449497,70.5 - 72.09,71.21,0.0,0.0,8,10,finmb_315179920,NasdaqGS,"IGM Biosciences, Inc.",USD,146278,105200,-14.272366,8.354,77.34857,-5.558571,-0.07186391,78.346085,-6.5560837,-0.08368106,2299146496,-36.627552,8.593488,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"IGM Biosciences, Inc.",71.79,1630526402,0.58000183,71.66,72.09,70.5,91255,,,,133.0,42.0,77.35,78.35,146.28k,105.2k,25.59M,,7.98M,43.15%,65.31%,2.95M,23.02,36.77%,9.20%,2.95M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-24.96%,-43.54%,,,,-39.16M,-113.1M,-115.25M,-26.20,,281.44M,8.78,12.64M,3.92,15.22,8.35,-92.45M,-74.58M,Value,94043,Healthcare,144,9,8,"IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.",Mountain View,650 965 7873,CA,10,1609372800,1625097600,5,United States,http://igmbio.com,86400,8,325 East Middlefield Road,Biotechnology
t-2,IGMS,381815000.0,25594700,19599000,,-24622000,,-24622000,5140000,-12124000,-24739000,-24739000,,,,,,0,0,24739000,12124000,117000,,-24622000,-24622000,570030000.0,26817000.0,381815000.0,,408632000.0,319000.0,-188560000.0,26000.0,548000.0,241080000.0,17240000.0,26000.0,34812000.0,373272000.0,,125189000.0,7924000.0,27358000.0,2464000.0,20650000.0,215910000.0,-4350000.0,216643000.0,213796000.0,-238000.0,-22764000.0,312000.0,3432000.0,-6708000.0,-495000.0,356032000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,29.79,0.70928574,42.0 - 133.0,-61.21,-0.46022555,42.0,133.0,1617134400,1635942600,1636374600,-26.204,-1.96,-5.03,0.81449497,70.5 - 72.09,71.21,0.0,0.0,8,10,finmb_315179920,NasdaqGS,"IGM Biosciences, Inc.",USD,146278,105200,-14.272366,8.354,77.34857,-5.558571,-0.07186391,78.346085,-6.5560837,-0.08368106,2299146496,-36.627552,8.593488,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"IGM Biosciences, Inc.",71.79,1630526402,0.58000183,71.66,72.09,70.5,91255,,,,133.0,42.0,77.35,78.35,146.28k,105.2k,25.59M,,7.98M,43.15%,65.31%,2.95M,23.02,36.77%,9.20%,2.95M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-24.96%,-43.54%,,,,-39.16M,-113.1M,-115.25M,-26.20,,281.44M,8.78,12.64M,3.92,15.22,8.35,-92.45M,-74.58M,Value,94043,Healthcare,144,9,8,"IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.",Mountain View,650 965 7873,CA,10,1609372800,1625097600,5,United States,http://igmbio.com,86400,8,325 East Middlefield Road,Biotechnology
t-3,IGMS,188176000.0,25594700,15829000,,-20270000,,-20270000,4732000,-8831000,-20561000,-20561000,,,,,,0,0,20561000,8831000,291000,,-20270000,-20270000,351694000.0,23541000.0,188176000.0,,211717000.0,307000.0,-163938000.0,113000.0,486000.0,27284000.0,13282000.0,113000.0,26579000.0,184652000.0,,152952000.0,3189000.0,18050000.0,639000.0,11485000.0,-917000.0,943000.0,8000.0,-4507000.0,-925000.0,-15075000.0,248000.0,3365000.0,-6565000.0,-495000.0,171370000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,False,False,0,29.79,0.70928574,42.0 - 133.0,-61.21,-0.46022555,42.0,133.0,1617134400,1635942600,1636374600,-26.204,-1.96,-5.03,0.81449497,70.5 - 72.09,71.21,0.0,0.0,8,10,finmb_315179920,NasdaqGS,"IGM Biosciences, Inc.",USD,146278,105200,-14.272366,8.354,77.34857,-5.558571,-0.07186391,78.346085,-6.5560837,-0.08368106,2299146496,-36.627552,8.593488,15,America/New_York,EDT,-14400000,2,NMS,PRE,us_market,"IGM Biosciences, Inc.",71.79,1630526402,0.58000183,71.66,72.09,70.5,91255,,,,133.0,42.0,77.35,78.35,146.28k,105.2k,25.59M,,7.98M,43.15%,65.31%,2.95M,23.02,36.77%,9.20%,2.95M,,,,,,0.00%,,,,,"Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-24.96%,-43.54%,,,,-39.16M,-113.1M,-115.25M,-26.20,,281.44M,8.78,12.64M,3.92,15.22,8.35,-92.45M,-74.58M,Value,94043,Healthcare,144,9,8,"IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.",Mountain View,650 965 7873,CA,10,1609372800,1625097600,5,United States,http://igmbio.com,86400,8,325 East Middlefield Road,Biotechnology
